Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 2
2014 1
2015 1
2016 1
2018 1
2019 2
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, Bittner T, Ovod V, Verberk IMW, Toba K, Nakamura A, Bateman RJ, Blennow K, Hansson O. Janelidze S, et al. Among authors: sarasa l. JAMA Neurol. 2021 Nov 1;78(11):1375-1382. doi: 10.1001/jamaneurol.2021.3180. JAMA Neurol. 2021. PMID: 34542571 Free PMC article.
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, Ashton NJ, Pesini P, Sarasa L, Allué JA, Teunissen CE, Dage JL, Blennow K, Mattsson-Carlgren N, Hansson O. Janelidze S, et al. Among authors: sarasa l. Alzheimers Dement. 2022 Feb;18(2):283-293. doi: 10.1002/alz.12395. Epub 2021 Jun 20. Alzheimers Dement. 2022. PMID: 34151519
The global Alzheimer's Association round robin study on plasma amyloid β methods.
Pannee J, Shaw LM, Korecka M, Waligorska T, Teunissen CE, Stoops E, Vanderstichele HMJ, Mauroo K, Verberk IMW, Keshavan A, Pesini P, Sarasa L, Pascual-Lucas M, Fandos N, Allué JA, Portelius E, Andreasson U, Yoda R, Nakamura A, Kaneko N, Yang SY, Liu HC, Palme S, Bittner T, Mawuenyega KG, Ovod V, Bollinger J, Bateman RJ, Li Y, Dage JL, Stomrud E, Hansson O, Schott JM, Blennow K, Zetterberg H. Pannee J, et al. Among authors: sarasa l. Alzheimers Dement (Amst). 2021 Oct 14;13(1):e12242. doi: 10.1002/dad2.12242. eCollection 2021. Alzheimers Dement (Amst). 2021. PMID: 34692980 Free PMC article.
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
Pérez-Grijalba V, Arbizu J, Romero J, Prieto E, Pesini P, Sarasa L, Guillen F, Monleón I, San-José I, Martínez-Lage P, Munuera J, Hernández I, Buendía M, Sotolongo-Grau O, Alegret M, Ruiz A, Tárraga L, Boada M, Sarasa M; AB255 Study Group. Pérez-Grijalba V, et al. Among authors: sarasa l. Alzheimers Res Ther. 2019 Dec 1;11(1):96. doi: 10.1186/s13195-019-0549-1. Alzheimers Res Ther. 2019. PMID: 31787105 Free PMC article.
Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial.
Lacosta AM, Pascual-Lucas M, Pesini P, Casabona D, Pérez-Grijalba V, Marcos-Campos I, Sarasa L, Canudas J, Badi H, Monleón I, San-José I, Munuera J, Rodríguez-Gómez O, Abdelnour C, Lafuente A, Buendía M, Boada M, Tárraga L, Ruiz A, Sarasa M. Lacosta AM, et al. Among authors: sarasa l. Alzheimers Res Ther. 2018 Jan 29;10(1):12. doi: 10.1186/s13195-018-0340-8. Alzheimers Res Ther. 2018. PMID: 29378651 Free PMC article. Clinical Trial.
13 results